Gilead rises after Q3 beat and higher 2026 sales outlook

Gilead Sciences (GILD) is up 3.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a strong third-quarter earnings report that came in above expectations, along with a higher full-year product sales outlook. Investors also appear to be responding to continued momentum in Gilead’s HIV franchise, which remains the company’s core growth engine.

Details:

Third-quarter 2026 product sales rose 13% year over year to $8.3 billion, helped by stronger HIV, Trodelvy, and Livdelzi sales.

Non-GAAP diluted earnings per share was $2.55 for the quarter, while HIV product sales increased 18% to $6.2 billion.

Gilead lifted its 2026 product sales guidance to $31.0 billion to $31.3 billion, up from its prior range of $30.1 billion to $30.4 billion.

Within HIV, Biktarvy sales grew 10% and Descovy sales jumped 49%, reinforcing the view that the company’s largest business is still expanding.

Sources:

Gilead Sciences Investor Relations, Finviz, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$GILD Insider Trading Activity

$GILD insiders have traded $GILD stock on the open market 42 times in the past 6 months. Of those trades, 0 have been purchases and 42 have been sales.

Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:

DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 13 sales selling 75,000 shares for an estimated $10,269,039.
JOHANNA MERCIER (Chief Comm & Corp Aff Officer) has made 0 purchases and 14 sales selling 68,000 shares for an estimated $9,192,932.
ANTHONY WELTERS has made 0 purchases and 4 sales selling 18,000 shares for an estimated $2,675,219.
ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 18,000 shares for an estimated $2,482,396.
JEFFREY BLUESTONE has made 0 purchases and 5 sales selling 5,000 shares for an estimated $725,077.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$GILD Hedge Fund Activity

We have seen 1,114 institutional investors add shares of $GILD stock to their portfolio, and 1,045 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

INVESCO LTD. added 24,292,815 shares (+156.5%) to their portfolio in Q2 2026, for an estimated $3,069,154,247
JPMORGAN CHASE & CO added 20,820,621 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,630,477,257
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 8,155,281 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,030,338,201
CAPITAL RESEARCH GLOBAL INVESTORS removed 7,734,237 shares (-28.5%) from their portfolio in Q2 2026, for an estimated $977,143,502
FMR LLC removed 5,035,474 shares (-7.0%) from their portfolio in Q2 2026, for an estimated $636,181,785
SG AMERICAS SECURITIES, LLC added 3,812,458 shares (+393.8%) to their portfolio in Q2 2026, for an estimated $481,665,943
PRICE T ROWE ASSOCIATES INC /MD/ added 3,748,586 shares (+14.3%) to their portfolio in Q2 2026, for an estimated $473,596,355

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$GILD Congressional Stock Trading

Members of Congress have traded $GILD stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:

REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/06 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$GILD Price Targets

Multiple analysts have issued price targets for $GILD recently. We have seen 6 analysts offer price targets for $GILD in the last 6 months, with a median target of $155.5.

Here are some recent targets:

Matthew Harrison from Morgan Stanley set a target price of $166.0 on 07/08/2026
Gregory Renza from Truist Securities set a target price of $156.0 on 07/07/2026
Brian Abrahams from RBC Capital set a target price of $120.0 on 07/07/2026
Morten Herholdt from HSBC set a target price of $155.0 on 07/06/2026
Carter Gould from Cantor Fitzgerald set a target price of $155.0 on 07/06/2026
Michael Okunewitch from Maxim Group set a target price of $165.0 on 05/20/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.